Blood Work for Protocol Monitoring: Which Labs to Track and What the Numbers Mean

Regular blood work is the only objective way to know whether a protocol is doing what you intend and not causing harm you cannot feel. At minimum, anyone running a peptide, hormone, or GLP-1 protocol should monitor: a comprehensive metabolic panel (CMP) for liver and kidney function, a complete blood count (CBC) for red and white blood cell health, a lipid panel for cardiovascular markers, fasting glucose and HbA1c for metabolic status, and protocol-specific markers (testosterone and estradiol for TRT, HbA1c and fasting insulin for GLP-1 agonists, IGF-1 for growth hormone peptides). Baseline labs before starting, then follow-up at 6-8 weeks and every 3-6 months thereafter.

A baseline panel gives you a snapshot of your health before you introduce any new variable. Without it, you cannot tell whether a change in your labs was caused by the protocol or was already there. This is not optional — it is the foundation of evidence-based self-tracking. The essential baseline includes: CBC (complete blood count) — measures red blood cells (hemoglobin, hematocrit), white blood cells, and platelets. Hematocrit is especially important for testosterone protocols because TRT increases red blood cell production, and elevated hematocrit (above 54%) increases the risk of blood clots. If your baseline hematocrit is already 50%, your provider needs to know before starting TRT. CMP (comprehensive metabolic panel) — includes liver enzymes (AST, ALT), kidney markers (BUN, creatinine, eGFR), electrolytes, and blood glucose. Liver enzymes matter because oral compounds and even some injectable peptides can stress the liver. Establishing a baseline lets you detect elevation early. Normal AST and ALT are typically 10-40 U/L. Mild elevation (40-80) warrants monitoring. Significant elevation (above 3x the upper limit) warrants stopping the protocol and consulting a provider. Lipid panel — total cholesterol, LDL, HDL, and triglycerides. Certain protocols (particularly anabolic compounds and some SARMs) can shift lipid profiles unfavorably, lowering HDL and raising LDL. Knowing your baseline separates pre-existing dyslipidemia from protocol-induced changes. Hormone panel — testosterone (total and free), estradiol, and SHBG for anyone considering testosterone-related protocols. Thyroid panel (TSH, free T4) for anyone on peptides that may affect thyroid function. Fasting insulin and HbA1c for GLP-1 protocols.

TRT (testosterone replacement therapy) monitoring: Total testosterone, free testosterone, estradiol, hematocrit, and PSA. Testosterone levels should be checked at trough (the day before or morning of your next injection for weekly protocols). Target ranges vary by provider, but most aim for total testosterone of 600-1,000 ng/dL. Estradiol should be monitored because testosterone aromatizes to estrogen — elevated estradiol (above 40-50 pg/mL in men) can cause water retention, mood changes, and gynecomastia. Hematocrit must stay below 54% — above this threshold, blood becomes too viscous and clot risk rises. PSA (prostate-specific antigen) should be checked annually as a prostate health screening. GLP-1 agonist monitoring: HbA1c (should decrease if protocol is working — target depends on clinical goals), fasting glucose, fasting insulin, lipid panel (GLP-1s often improve lipid profiles), and amylase/lipase (pancreatic enzymes — elevation could indicate pancreatitis, a rare but serious side effect). For weight management, tracking body composition metrics alongside labs gives a more complete picture than weight alone. Peptide protocols (BPC-157, GH secretagogues, etc.): IGF-1 is the primary marker for growth hormone-related peptides — it reflects integrated GH activity over time. Fasting glucose and HbA1c should be monitored because growth hormone opposes insulin, and prolonged GH elevation can impair glucose tolerance. CMP for liver and kidney function. CBC for general health surveillance. Dosed logs your lab results alongside your protocol timeline so you can visualize how markers change over time and share a complete history with your healthcare provider.

Testing frequency follows a pattern: baseline before starting, first follow-up at 6-8 weeks (to catch early problems and confirm the protocol is producing the expected biochemical changes), then every 3-6 months for ongoing monitoring. Stable protocols with consistent labs can stretch to every 6 months. New protocols, dose changes, or any concerning symptoms warrant earlier retesting. Single data points are almost useless. What matters is the trend. An ALT of 45 in isolation tells you nothing — it could be your normal baseline. An ALT that went from 22 to 45 to 78 over three tests tells you something is stressing the liver. This is why baseline matters and why consistent testing on the same schedule creates interpretable data. Always test under the same conditions. Fasting (10-12 hours, water only) for metabolic and lipid panels. Same time of day if possible — cortisol and testosterone both follow circadian patterns, so a 7am and a 3pm draw are not comparable. Same lab ideally — different labs use different assay methods and reference ranges, which introduces noise into your trend data. Reference ranges on lab reports are population norms, not optimal ranges. A fasting glucose of 99 mg/dL is within the reference range (typically 70-100) but is one point from pre-diabetic (100-125). A hematocrit of 53% is within some labs' reference range but is at the threshold where providers managing TRT get concerned. Context matters. A provider experienced with your specific protocol will interpret your labs differently than a general practitioner reading the same report. This content is for educational purposes only and does not constitute medical advice. Always work with a qualified healthcare professional who can interpret your lab results in the context of your specific health situation and protocol.